Your browser is no longer supported. Please, upgrade your browser.
Settings
ORPH [NASD]
Orphazyme A/S
Index- P/E- EPS (ttm)- Insider Own- Shs Outstand34.95M Perf Week-41.31%
Market Cap227.89M Forward P/E- EPS next Y-2.00 Insider Trans- Shs Float24.59M Perf Month18.33%
Income- PEG- EPS next Q-0.70 Inst Own0.50% Short Float0.14% Perf Quarter-49.02%
Sales- P/S- EPS this Y- Inst Trans- Short Ratio0.01 Perf Half Y-40.94%
Book/sh- P/B- EPS next Y40.10% ROA- Target Price10.50 Perf Year-
Cash/sh- P/C- EPS next 5Y- ROE- 52W Range4.75 - 77.77 Perf YTD-39.24%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-91.62% Beta-
Dividend %- Quick Ratio- Sales past 5Y- Gross Margin- 52W Low37.26% ATR5.79
Employees141 Current Ratio- Sales Q/Q- Oper. Margin- RSI (14)46.75 Volatility50.13% 89.56%
OptionableYes Debt/Eq- EPS Q/Q- Profit Margin- Rel Volume2.56 Prev Close7.33
ShortableNo LT Debt/Eq- Earnings- Payout- Avg Volume6.96M Price6.52
Recom3.00 SMA20-18.29% SMA50-19.51% SMA200-36.65% Volume17,852,561 Change-11.05%
Jun-21-21Downgrade Guggenheim Buy → Sell
Mar-30-21Downgrade BofA Securities Neutral → Underperform $13 → $5
Oct-26-20Initiated Guggenheim Buy $27
Oct-26-20Initiated BofA Securities Buy $13
Jun-21-21 12:39PM  
Jun-19-21 06:53AM  
Jun-18-21 04:11PM  
12:37PM  
06:53AM  
06:49AM  
06:17AM  
05:07AM  
01:56AM  
01:12AM  
01:00AM  
Jun-16-21 04:06PM  
Jun-15-21 12:46PM  
11:05AM  
Jun-11-21 10:12AM  
09:36AM  
09:17AM  
07:55AM  
03:42AM  
Jun-10-21 03:31PM  
May-18-21 02:18AM  
May-11-21 04:30PM  
May-07-21 10:32AM  
10:02AM  
01:00AM  
Apr-27-21 04:05PM  
Apr-22-21 12:34AM  
Apr-01-21 04:30PM  
Mar-29-21 02:45PM  
12:29PM  
01:00AM  
Mar-25-21 03:48PM  
03:37PM  
03:20PM  
01:53PM  
Mar-03-21 01:06PM  
10:00AM  
Mar-02-21 01:00AM  
Mar-01-21 01:00AM  
Feb-26-21 03:38PM  
Feb-25-21 04:01PM  
Feb-04-21 07:30AM  
Feb-01-21 02:11PM  
02:01PM  
Jan-18-21 10:08AM  
Jan-04-21 10:49AM  
Dec-31-20 02:00PM  
Dec-27-20 05:00PM  
Dec-10-20 04:36PM  
Dec-09-20 04:58AM  
Dec-07-20 10:50AM  
Dec-02-20 07:38AM  
Nov-30-20 09:14PM  
Nov-09-20 01:00AM  
Nov-03-20 04:44PM  
Oct-27-20 12:10PM  
Oct-23-20 08:20AM  
Oct-21-20 10:37AM  
Oct-16-20 11:29AM  
Oct-09-20 10:09AM  
Oct-08-20 11:05AM  
Oct-05-20 11:28AM  
04:28AM  
Oct-02-20 10:21AM  
Oct-01-20 02:25AM  
Sep-30-20 08:21AM  
06:10AM  
Sep-28-20 10:45PM  
10:27PM  
Sep-25-20 03:07AM  
Orphazyme A/S, a biopharmaceutical company, develops therapies for the treatment of neurodegenerative orphan diseases. The company focuses on the amplification of heat-shock proteins to develop and commercialize therapeutics for diseases caused by protein misfolding and aggregation, and lysosomal dysfunction, including lysosomal storage and neuromuscular degenerative diseases. Its lead candidate is the Arimoclomol, which is in clinical development for four orphan diseases, including Niemann-Pick disease type C, Amyotrophic Lateral Sclerosis, Inclusion Body Myositis, and Gaucher disease. The company was incorporated in 2009 and is headquartered in Copenhagen, Denmark.